OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease
Katherine R. Tuttle, Peter Rossing, Sibylle J. Hauske, et al.
American Journal of Nephrology (2023) Vol. 55, Iss. 2, pp. 262-272
Open Access | Times Cited: 8
Katherine R. Tuttle, Peter Rossing, Sibylle J. Hauske, et al.
American Journal of Nephrology (2023) Vol. 55, Iss. 2, pp. 262-272
Open Access | Times Cited: 8
Showing 8 citing articles:
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani, et al.
The Lancet (2023) Vol. 403, Iss. 10424, pp. 379-390
Open Access | Times Cited: 70
Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani, et al.
The Lancet (2023) Vol. 403, Iss. 10424, pp. 379-390
Open Access | Times Cited: 70
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
Stefan R. Bornstein, Dick de Zeeuw, Hiddo J.L. Heerspink, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2128-2138
Open Access | Times Cited: 10
Stefan R. Bornstein, Dick de Zeeuw, Hiddo J.L. Heerspink, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2128-2138
Open Access | Times Cited: 10
Aldosterone Synthase Inhibitor BI 690517: Specificity for Mineralocorticoid Receptor
Andrew Treihaft, Manish A. Parikh, Kaedrea A. Jackson, et al.
Cardiology in Review (2025)
Closed Access | Times Cited: 1
Andrew Treihaft, Manish A. Parikh, Kaedrea A. Jackson, et al.
Cardiology in Review (2025)
Closed Access | Times Cited: 1
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Parminder K. Judge, Katherine R. Tuttle, Natalie Staplin, et al.
Nephrology Dialysis Transplantation (2024)
Open Access | Times Cited: 5
Parminder K. Judge, Katherine R. Tuttle, Natalie Staplin, et al.
Nephrology Dialysis Transplantation (2024)
Open Access | Times Cited: 5
Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors
Jared M. Feldman, William H. Frishman, Wilbert S. Aronow
Cardiology in Review (2024)
Closed Access | Times Cited: 4
Jared M. Feldman, William H. Frishman, Wilbert S. Aronow
Cardiology in Review (2024)
Closed Access | Times Cited: 4
Arterial hypertension—clinical trials update 2024
Mert Tokcan, Lucas Lauder, Felix Götzinger, et al.
Hypertension Research (2024)
Closed Access | Times Cited: 1
Mert Tokcan, Lucas Lauder, Felix Götzinger, et al.
Hypertension Research (2024)
Closed Access | Times Cited: 1
Neue Antihypertensiva im Renin-Angiotensin-Aldosteron-System
Markus van der Giet
CardioVasc (2024) Vol. 24, Iss. 1, pp. 33-38
Closed Access
Markus van der Giet
CardioVasc (2024) Vol. 24, Iss. 1, pp. 33-38
Closed Access
